TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15633811

Group type: EXPERIMENTAL
Intervention: Real intradermal acupuncture on shen‐men (He‐7) and nei‐kuan (EH‐6) for 2 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture on the same points for 2 days
Number of subjects: 30
Study: 11319675

Group type: EXPERIMENTAL
Intervention: BIM (Breathe with Interactive Music)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Walkman (control)
Number of subjects: 33
Study: 9431347

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy and monitoring by experienced physicians and surgeons for patients with fulminant colitis, toxic megacolon, or perforation.
Number of subjects: 0
Study: 7943771

Group type: EXPERIMENTAL
Intervention: Autologous + leukocyte‐depleted red blood cell transfusion (800 +/- 200 mL autologous blood and 2.2 +/- 2.0 units of SAGM red blood cells)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard allogeneic red blood cell transfusion (5.5 +/- 1.4 units of SAGM red blood cells)
Number of subjects: 24
Study: 3062352

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (Diazepam, Flunitrazepam, Midazolam)
Number of subjects: 120
Study: 31826232

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Number of subjects: 44

Group type: COMPARATOR
Intervention: saline
Number of subjects: 44
Study: 31504126

Group type: EXPERIMENTAL
Intervention: 10 years of tamoxifen treatment
Number of subjects: 583

Group type: COMPARATOR
Intervention: 5 years of tamoxifen treatment
Number of subjects: 583
Study: 28682965

Group type: EXPERIMENTAL
Intervention: Temporary defunctioning stoma
Number of subjects: 98

Group type: COMPARATOR
Intervention: No temporary defunctioning stoma
Number of subjects: 98
Study: 25945500

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 104
Study: 23716471

Group type: EXPERIMENTAL
Intervention: Toxoplasma gondii infection
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus infection
Number of subjects: 410
Study: 22137077

Group type: EXPERIMENTAL
Intervention: Initial conservative management without cardiac catheterization
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Initial medical therapy after publication of trial results
Number of subjects: 499
Study: 19245713

Group type: EXPERIMENTAL
Intervention: Linear mixed-effects models for continuous outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinary logistic regression for binary outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed models
Number of subjects: 0
Study: 15992835

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dyslexia subjects
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Total MPA and FA measures
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High palate (individual MPA item)
Number of subjects: 51
Study: 14700145

Group type: EXPERIMENTAL
Intervention: Multivitamins and folic acid supplementation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Multivitamins only (Control)
Number of subjects: 29
Study: 11967798

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 17
Study: 8976781

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone cream applied twice daily for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neutral cream (Vaseline) applied twice daily for 4 weeks
Number of subjects: 40
Study: 1353011

Group type: EXPERIMENTAL
Intervention: L-threonine (Thr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Vitamin B or Carnitine)
Number of subjects: 30
Study: 6396839

Group type: EXPERIMENTAL
Intervention: Cloxacillin (2 g intravenously 2 hours before operation, followed by 1 g every 6 hours for 2 days and 1 g orally for 8 more days postoperatively)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 30447035

Group type: EXPERIMENTAL
Intervention: Chronic disease status
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Health service utilisation
Number of subjects: 237
Study: 30052055

Group type: EXPERIMENTAL
Intervention: MG-NMES
Number of subjects: 20

Group type: COMPARATOR
Intervention: C-NMES
Number of subjects: 20
Study: 27654602

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (wearable device and web interface)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Standard intervention (standard behavioral weight loss intervention)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Both groups (enhanced and standard interventions)
Number of subjects: 471
Study: 24906822

Group type: EXPERIMENTAL
Intervention: Isolated diastolic hypertension (DBP24≥80 mm Hg)
Number of subjects: 8341

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (SBP24≥130 mm Hg)
Number of subjects: 8341

Group type: EXPERIMENTAL
Intervention: Mixed diastolic plus systolic hypertension
Number of subjects: 8341

Group type: EXPERIMENTAL
Intervention: DBP24 below age 50
Number of subjects: 8341

Group type: EXPERIMENTAL
Intervention: SBP24 above age 50
Number of subjects: 8341
Study: 22513516

Group type: EXPERIMENTAL
Intervention: 10% HES 130/0.4
Number of subjects: 76

Group type: COMPARATOR
Intervention: 10% HES 200/0.5
Number of subjects: 76
Study: 19852877

Group type: EXPERIMENTAL
Intervention: Thought suppression demonstration
Number of subjects: 91
Study: 17845270

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20-140 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11694609

Group type: EXPERIMENTAL
Intervention: Iron supplementation (10 mg/d)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Iron + Zinc supplementation (10 mg of each/d)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 9212763

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg intravenously)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 8134718

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.6 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral prednisone 10 mg daily
Number of subjects: 40
Study: 3306546

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% levobunolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily instillation for 1 week
Number of subjects: 0
Study: 29754267

Group type: EXPERIMENTAL
Intervention: Theory-based tri-focal intervention
Number of subjects: 432

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Both intervention and comparison groups
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Intervention group (men)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Intervention group (women)
Number of subjects: 432
Study: 28177703

Group type: EXPERIMENTAL
Intervention: Moderate-load (50% 1RM) explosive contractions (MLEC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Heavy-load (80% 1-repetition maximum (1RM)) explosive contractions (HLEC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heavy-load, controlled (2 s) (HLCC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Condition × sex interaction for blood lactate changes
Number of subjects: 15
Study: 26211765

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA in parenteral nutrition
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (without omega-3 PUFA in parenteral nutrition)
Number of subjects: 47
Study: 23205864

Group type: EXPERIMENTAL
Intervention: Micronized progesterone tablets 200 mg vaginally daily (Group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 100 mg progesterone intramuscular every third day (Group B)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intramuscular progesterone (Group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Group A)
Number of subjects: 160
Study: 21999153

Group type: EXPERIMENTAL
Intervention: Taijiquan classes (n=76)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Special recreation (control group, n=132)
Number of subjects: 208
Study: 18280415

Group type: EXPERIMENTAL
Intervention: Single sagittal radius femoral design
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multiradius femoral design
Number of subjects: 100
Study: 17080540

Group type: EXPERIMENTAL
Intervention: Xiong‐gui‐jiao‐ai‐tang (7.5 g/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 72
Study: 14767417

Group type: EXPERIMENTAL
Intervention: Theophylline (4.5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10954004

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (nitrendipine or nifedipine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No calcium antagonists
Number of subjects: 50
Study: 8660034

Group type: EXPERIMENTAL
Intervention: Normal energy content meals (1700 kcal)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low energy content meals (260 kcal)
Number of subjects: 28
Study: 1553052

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (orally administered)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin calcium
Number of subjects: 100
Study: 29032877

Group type: EXPERIMENTAL
Intervention: Intraoperative instillation of 7.5mg of ropivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard procedure (control)
Number of subjects: 72
Study: 27297634

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 3084

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 3084

Group type: EXPERIMENTAL
Intervention: Anxiolytic or hypnotic drugs
Number of subjects: 3084

Group type: EXPERIMENTAL
Intervention: Self-reported depression and anxiety
Number of subjects: 3084

Group type: EXPERIMENTAL
Intervention: Self-reported depression with insomnia
Number of subjects: 3084
Study: 24694335

Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin D3
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D3
Number of subjects: 644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Genetic factors (SNPs in CYP2R1, IRF4, MC1R, CYP27B1, VDR, TYRP1, MCM6, HERC2)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Models including SNPs
Number of subjects: 644
Study: 23341518

Group type: EXPERIMENTAL
Intervention: Anthracycline-only chemotherapy (doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin plus cyclophosphamide followed by CMF)
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Chemotherapy combining doxorubicin and docetaxel (doxorubicin plus docetaxel followed by CMF or doxorubicin followed by docetaxel followed by CMF)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Anthracycline-only chemotherapy
Number of subjects: 2009
Study: 20595800

Group type: EXPERIMENTAL
Intervention: Pegvisomant (10 to 40 mg/day for 18 months)
Number of subjects: 10
Study: 18675295

Group type: EXPERIMENTAL
Intervention: Groningen Active Living Model (GALM) recruitment strategy
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Cost of recruitment
Number of subjects: 315
Study: 17141642

Group type: EXPERIMENTAL
Intervention: Zaltoprofen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) with zaltoprofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiotherapy (PT) without zaltoprofen
Number of subjects: 40
Study: 14682400

Group type: EXPERIMENTAL
Intervention: Experimental intervention (SexG), 6 group sessions
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control intervention, 6-session HIV educational program
Number of subjects: 257
Study: 10876460

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 22
Study: 8959150

Group type: EXPERIMENTAL
Intervention: MB‐Check system
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Bactec‐460 system
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Lowenstein‐Jensen (LJ) medium
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Combination of Bactec and MB‐Check systems
Number of subjects: 1840
Study: 1530193

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza A (H3N2) virus vaccine
Number of subjects: 523
Study: 4064565

Group type: EXPERIMENTAL
Intervention: Adrenaline 50 ng min‐1 kg‐1 (high A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Adrenaline 10 ng min‐1 kg‐1 (low A)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sodium chloride solution (saline: 154 mmol of NaCl/l) plus ascorbic acid, 1 mg/ml (control)
Number of subjects: 7
Study: 31415040

Group type: EXPERIMENTAL
Intervention: Male partners reporting medium acceptance of intimate partner violence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male partners reporting low acceptance of intimate partner violence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender equality measured by decision making power
Number of subjects: 0
Study: 30560721

Group type: EXPERIMENTAL
Intervention: Video lectures
Number of subjects: 205

Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Subjective evaluation of learning atmosphere, ability to concentrate, presence of other students, and acoustic intelligibility
Number of subjects: 205
Study: 26582140

Group type: EXPERIMENTAL
Intervention: Nicotine gum combined with behavioral reduction counseling (BR)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Behavioral reduction counseling (BR)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Nicotine gum without motivational interviewing (MI)
Number of subjects: 517
Study: 24604409

Group type: EXPERIMENTAL
Intervention: MAG gel in sugar cookies (40 g)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MAG gel in baked products (high and low moisture)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Industry standard stearic‐rich shortening
Number of subjects: 18
Study: 22801836

Group type: EXPERIMENTAL
Intervention: Peribulbar injection of gadolinium and lidocaine hydrochloride, 2%, without epinephrine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of gadolinium and lidocaine hydrochloride, 2%, without epinephrine
Number of subjects: 4
Study: 20131296

Group type: EXPERIMENTAL
Intervention: High-dose IV cyclophosphamide (50 mg/kg daily for 4 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional treatment (monthly IV cyclophosphamide at 750 mg/m2 for 6 months followed by quarterly IV cyclophosphamide for 2 years)
Number of subjects: 51
Study: 18475047

Group type: EXPERIMENTAL
Intervention: Thin layer smears
Number of subjects: 3875

Group type: COMPARATOR
Intervention: Conventional smears
Number of subjects: 3875
Study: 15954952

Group type: EXPERIMENTAL
Intervention: Xenon 60-65% in oxygen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Propofol 3 mg/kg/h
Number of subjects: 26
Study: 12550813

Group type: EXPERIMENTAL
Intervention: EMG-force model
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 2
Study: 10624427

Group type: EXPERIMENTAL
Intervention: Foldable acrylic intraocular lens (IOL), n = 38
Number of subjects: 67

Group type: COMPARATOR
Intervention: Rigid polymethyl-methacrylate (PMMA) IOL, n = 29
Number of subjects: 67

Group type: COMPARATOR
Intervention: Age-matched normal subjects, n = 28
Number of subjects: 67
Study: 8750406

Group type: EXPERIMENTAL
Intervention: famotidine 20 mg BID
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg BID
Number of subjects: 172

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 172
Study: 2027977

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 6799401

Group type: EXPERIMENTAL
Intervention: Nutro-Drip
Number of subjects: 40
Study: 31618056

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over the left primary motor cortex (A‐tDCS‐M1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over Broca's area
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 52
Study: 28285641

Group type: EXPERIMENTAL
Intervention: EAA mixture (40% leucine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: TAA mixture (balanced free EAAs and non-EAAs as present in whey protein)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both mixtures
Number of subjects: 42
Study: 26669545

Group type: EXPERIMENTAL
Intervention: Immediate post-extractive implants
Number of subjects: 106

Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 106
Study: 25122437

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (B+E)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Bevacizumab plus placebo (B+P)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (B+E) in patients with EGFR mutation-positive NSCLC
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (B+E) in patients with KRAS wild-type disease
Number of subjects: 743
Study: 22964325

Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG 1064-nm laser treatment (8 sessions with a one-week interval)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG 1064-nm laser treatment (4 sessions with a one-week interval)
Number of subjects: 33
Study: 19772185

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate with KCl (test product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucosamine sulfate with NaCl (reference product)
Number of subjects: 24
Study: 17383650

Group type: EXPERIMENTAL
Intervention: AR‐PBS stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: AR‐PBS and PBS
Number of subjects: 0
Study: 15523488

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (86 mg/day) for 2 months (study 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (86 mg/day) for 3 months (study 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 2 months (study 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 1 month (study 2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation
Number of subjects: 25
Study: 11772475

Group type: EXPERIMENTAL
Intervention: Methadone medical maintenance (MMM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine methadone treatment
Number of subjects: 73
Study: 10543767

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 10 days
Number of subjects: 15
Study: 8529853

Group type: EXPERIMENTAL
Intervention: Verapamil (i.v.; 10 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (s.l.; 5-10 mg)
Number of subjects: 48
Study: 2180591

Group type: EXPERIMENTAL
Intervention: Perhexiline maleate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6244079

Group type: EXPERIMENTAL
Intervention: Combined radiation therapy and CCNU therapy (Group A: 26 cases)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CCNU given orally every 6‐8 weeks (Group B: 27 cases)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard radiation therapy alone (Group C: 50 cases)
Number of subjects: 103
Study: 30187910

Group type: EXPERIMENTAL
Intervention: GoldieBlox (packaged for girls)
Number of subjects: 61

Group type: COMPARATOR
Intervention: BobbyBlox (packaged for boys)
Number of subjects: 61
Study: 30998689

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with VVs
Number of subjects: 408455

Group type: EXPERIMENTAL
Intervention: Genetic correlation analysis
Number of subjects: 408455

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 408455

Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis
Number of subjects: 408455

Group type: EXPERIMENTAL
Intervention: Pleiotropic effects of VVs-associated variants
Number of subjects: 408455

Group type: EXPERIMENTAL
Intervention: Genetic overlap analysis
Number of subjects: 408455
Study: 27826985

Group type: EXPERIMENTAL
Intervention: CRYO
Number of subjects: 153

Group type: COMPARATOR
Intervention: RF
Number of subjects: 153
Study: 25655663

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 409

Group type: COMPARATOR
Intervention: Receipt of a brief message
Number of subjects: 409
Study: 23479393

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg po preoperatively followed by 200 mg po every eight hours for two days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 101
Study: 21216197

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 50
Study: 19135281

Group type: EXPERIMENTAL
Intervention: Intervention group (n=184)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (n=185)
Number of subjects: 369
Study: 17316648

Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine (5-mL uterine instillation of 2% lidocaine) plus buccal misoprostol (200-microg tablet)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (saline solution) plus buccal misoprostol (200-microg tablet)
Number of subjects: 126
Study: 15792015

Group type: EXPERIMENTAL
Intervention: Vibovitmama supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11099427

Group type: EXPERIMENTAL
Intervention: IV pentobarbital (mean dose 3.75 ± 1.10 mg/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: IV midazolam (mean dose 0.2 ± 0.03 mg/kg)
Number of subjects: 55
Study: 9768320

Group type: EXPERIMENTAL
Intervention: Topical decongestion
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: External nasal dilator
Number of subjects: 105